In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Oxygen therapy in suspected acute myocardial infarction and concurrent chronic obstructive pulmonary disease: a prespecified subgroup analysis from the DETO2X-AMI trial

Session Coronary artery disease and comorbidities

Speaker Pontus Andell

Event : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Non-pharmacological Treatment
  • Session type : Rapid Fire Abstracts

Authors : P Andell (Lund,SE), SK James (Uppsala,SE), O Ostlund (Uppsala,SE), T Yndigegn (Lund,SE), D Sparv (Lund,SE), J Pernow (Stockholm,SE), T Jernberg (Stockholm,SE), B Lindahl (Uppsala,SE), J Herlitz (Gothenburg,SE), D Erlinge (Lund,SE), R Hofmann (Stockholm,SE)

Authors:
P. Andell1 , S.K. James2 , O. Ostlund2 , T. Yndigegn1 , D. Sparv1 , J. Pernow3 , T. Jernberg4 , B. Lindahl2 , J. Herlitz5 , D. Erlinge1 , R. Hofmann3 , 1Lund University, Skane University Hospital, Department of Cardiology - Lund - Sweden , 2Uppsala Clinical Research Center - Uppsala - Sweden , 3Karolinska Institute - Stockholm - Sweden , 4Danderyd University Hospital - Stockholm - Sweden , 5Sahlgrenska University, Department of Cardiology - Gothenburg - Sweden ,

Topic(s):
Coronary Artery Disease: Non-pharmacological Treatment

Citation:
European Heart Journal ( 2019 ) 40 ( Supplement ), 1288

Background: The DETermination of the role of Oxygen in suspected Acute Myocardial Infarction (DETO2X-AMI) trial did not find any benefit of oxygen therapy compared to ambient air in normoxemic patients with suspected acute myocardial infarction (AMI). Patients with chronic obstructive pulmonary disease (COPD) may both benefit and be harmed by supplemental oxygen. Thus, we evaluated the effect of routine oxygen therapy compared to ambient air in normoxemic COPD patients with suspected AMI.

Methods and results: A total of 6629 patients with suspected AMI were randomized in the DETO2X-AMI trial to oxygen or ambient air. In the oxygen group (n=3311) and the ambient air group (n=3318), 155 and 141 patients, respectively, had COPD (prevalence of 4.5%). Patients with COPD were older, had more comorbid conditions and experienced a two-fold higher risk of death at one year (COPD: 32/296 [10.8%] vs. non-COPD 302/6333 [4.8%]). Oxygen therapy compared to ambient air was not associated with improved outcomes at 365 days (COPD: all-cause mortality HR 0.99 [95% CI 0.50–1.99, interaction-p=0.96]; cardiovascular death HR 0.80 [0.32–2.04, interaction-p=0.59]; rehospitalization with AMI or death HR 1.27 [0.71–2.28, interaction-p=0.46]; hospitalization for heart failure or death HR 1.08 [0.61–1.91, interaction-p=0.77]); there were no significant treatment-by-COPD interactions.

Conclusions: Although COPD patients had twice the mortality rate compared to non-COPD patients, this prespecified subgroup analysis from the DETO2X-AMI trial on oxygen therapy versus ambient air in normoxemic COPD patients with suspected AMI revealed no evidence for benefit of routine oxygen therapy consistent with the main trial's findings.

Outcome

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are